Kevin Brennan - 01 Oct 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
SVP, FINANCE AND ACCOUNTING
Signature
/s/ Julia Walcott, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
01 Oct 2024
Transactions value $
$0
Form type
4
Date filed
02 Oct 2024, 17:15
Previous filing
03 May 2024
Next filing
03 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +26K $0.00 26K 01 Oct 2024 Common Stock 26K $0.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on October 1, 2024 and will vest as to 100% of the shares underlying the option on September 30, 2025, subject to the Reporting Person's continued service to the Issuer or its subsidiaries through the vesting date.